Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis.
暂无分享,去创建一个
F. Valderrábano | M. Goicoechea | E. Verde | C. Caramelo | F Valderrábano | M Goicoechea | C Caramelo | P Rodriguez | E Verde | E Gruss | M Albalate | A Ortiz | S Casado | E. Gruss | M. Albalate | S. Casado | P. Rodríguez | A. Ortiz | C. Caramelo | F. Valderrábano | M. Goicoechea | Patrocinio Rodriguez | Enrique Gruss | Marta Albalate | Alberto Ortiz | Santos Casado
[1] M. Goicoechea,et al. Antiplatelet therapy alters iron requirements in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] E. Friedman,et al. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. , 1996, The New England journal of medicine.
[3] J. Bergström,et al. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] I. Macdougall,et al. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] B. Danielson. R-HuEPO hyporesponsiveness--who and why? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] R. Hye,et al. Management of infectious and cutaneous complications in vascular access. , 1997, Seminars in Vascular Surgery.
[8] F. Valderrábano,et al. Erythropoietin in chronic renal failure. , 1996, Kidney international.
[9] T. Drüeke,et al. R-HuEPO hyporesponsiveness--who and why? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] E. Werner,et al. Immune activation and the anaemia associated with chronic inflammatory disorders , 1991, European journal of haematology.
[11] E W Young,et al. Dialysis dose, membrane type, and anemia control. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] F. Valderrábano,et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. , 2000, Journal of the American Society of Nephrology : JASN.
[13] C. Winearls,et al. Chairman's Workshop Report R-HuEPO hyporesponsiveness—who and why? , 1995 .
[14] I. Macdougall. Optimizing erythropoietin therapy. , 1999, Current opinion in hematology.
[15] N. Casadevall. Cellular mechanism of resistance to erythropoietin. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] K. Eckardt. Cardiovascular consequences of renal anaemia and erythropoietin therapy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] J. Stivelman,et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. , 1989, Kidney international.
[18] A. Konijn. 5 Iron metabolism in inflammation , 1994 .
[19] D. Rao,et al. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. , 1993, The New England journal of medicine.
[20] E. Barrett-Connor. Anemia and infection. , 1972, The American journal of medicine.
[21] C. Caramelo,et al. Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication. , 1995, Kidney International.
[22] M. Olivares,et al. Iron, anemia, and infection. , 2009, Nutrition reviews.
[23] J. Brock,et al. Role of iron metabolism in absorption and cellular uptake of aluminum. , 1991, Kidney international.
[24] V. Carreño,et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. , 1998, Kidney international.